Phio Pharmaceuticals Corp. (PHIO)
$0.98+1.03%Close
SELLBEAR · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $11M
- Beta
- 0.80
- P/E (TTM)
- -0.74
- Short % float
- 0.78%
- Days to cover
- 1.0
- SI change
- -40.3%
- 1W
- -1.01%
- 1M
- -2.97%
- vs SPY 1W
- -2.17%
- vs SPY 1M
- -5.96%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 10
- VALUE
- 17
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-52.4%
REV YoY-
ROE-87.4%
EPS YoY-
ROA-90.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.74
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B0.92
P/FCF-
EV/EBITDA0.11
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO15.87
ND/EBITDA-
BETA0.80
Company news
FAQ
- What is LOPJLB’s current signal on PHIO?
- LOPJLB’s latest quantitative signal on Phio Pharmaceuticals Corp. (PHIO) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is PHIO in?
- Phio Pharmaceuticals Corp. (PHIO) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Phio Pharmaceuticals Corp. (PHIO) do?
- Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene …